arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ
posted 17 hours ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Today the recently founded company ADx NeuroSciences NV entered into a license agreement with K.U.Leuven, the academic founder of ADx NeuroSciences. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates. ADx NeuroSciences is a new biotech company that focuses on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases. read more
VIB and Ghent University announce the launch of Q-Biologicals, a new startup dedicated to the production of biologicals, substances produced with the help of living, biological processes. Annie Van Broekhoven, former director Biological Operations at Innogenetics-Fujirebio, is the new CEO of Q-Biologicals. Investors are VIB, PMV, Life Sciences Research Partners (LSRP) and the recently established SOFI fund, an initiative of Flemish minister of Innovation Ingrid Lieten. read more
Opening of new laboratories on the Waterfront science park in Niel, Belgium Multiplicom nv, specialized in the development, production and commercialization of innovative molecular genetic tests, announces that it launches two new kits for cancer predisposition screening based on its Multiplexer™-technology. Concurrently the company will on September 23rd officially open its brand new laboratories on the Waterfront science park in Niel, Belgium. read more
Medisch onderzoek efficiënter en goedkoper maken. Dat is het doel van icoMetrix. Deze unieke spin-off helpt artsen en onderzoekers om relevante informatie uit medische beelden te halen. Dit vereist zeer specifieke kennis en vaardigheden. icoMetrix biedt deze slimme beeldverwerking aan en draagt zo bij tot betere, goedkopere en gepersonaliseerde geneeskunde. read more
TiGenix (NYSE EURONEXT: TIG) has entered into an agreement with its academic partners, the Catholic University Leuven (KULeuven) and Ghent University (UGent), the Dutch company Therosteon and a consortium of investors for the creation of a new small molecule drug development company, Arcarios, that will focus on the discovery and development of innovative, disease modifying drugs that target bone and joint diseases. TiGenix has a significant equity stake in this new company and retains the rights to drug candidates developed by Arcarios for local treatment of arthritic diseases. read more
